Biofilms Treatment Market to Grow at a CAGR of 7.5% to reach US$ 2,825.80 Million from 2019 to 2027

The biofilms treatment market was valued at US$ 1,590.31 million in 2019 and is projected to reach US$ 2,825.80 million by 2027; it is expected to grow at a CAGR of 7.5% during 2020–2027.

Biofilms are composed of mixed strains of fungi, bacteria, yeasts, algae, and other microbes. A biofilm develops on the wound surface when certain types of bacteria or fungi adhere to the wound surface and form a matrix over it. Viscous and shiny substances with unpleasant smell are secreted. The rising diabetes cases, increasing incidence of skin injuries due to burns and ulcers wounds, and growing number of surgical procedures across the world fuel the biofilms treatment market growth. Moreover, the rising number of innovations in wound care products is expected to drive market growth during the forecast period. However, the high cost associated with wound care management hinders the growth of the biofilms treatment market.

Lucrative Regions for Biofilms Treatment Market

Get more information on this report : Request Free Sample PDF

Market Insights

Increasing Incidence of Wounds and Ulcers

Rising risks associated with diabetes such as diabetic foot ulcers and pressure sores accelerate demand for advanced bioactive wound care management products. In addition, the prevalence of noncommunicable diseases is increasing due to factors such as antimicrobial resistance, unhealthy lifestyles, alcohol consumption, and smoking. As per the International Diabetes Federation, in 2019, ~463 million adults were affected by diabetes, and the number of adult patients suffering from diabetes is expected to reach 700 million by 2045. As per the International Diabetes Federation, diabetes patients are 15–40 times more likely to require lower-leg amputation. Approximately 85% of amputations are carried out due to the development of a neuropathic foot ulcer.

Product-Based Insights

Based on product, the biofilms treatment market is segmented into debridement equipment, gauzes and dressings, grafts and matrices, and other products. The gauzes and dressings segment held the largest share of the market in 2019. The same segment is anticipated to register the highest CAGR in the market during the forecast period. Many companies are developing advanced dressings to prevent biofilms. For instance, ConvaTec Inc. has developed Hydrofiber Technology, where the soft absorbent dressing material forms a gel when it comes in contact with wound fluid. The technology reduces the dead space where bacteria can grow, and it also provides rapid and sustained antimicrobial activity.

Gauzes are available in woven and nonwoven forms, which have high absorbency and can be applied on both infected and noninfected wounds.

Global Biofilms Treatment Market, by Product – 2019 and 2027

Get more information on this report : Request Free Sample PDF

Wound Type-Based Insights

Based on wound type, the biofilms treatment market is segmented into traumatic and surgical wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and other wounds. The traumatic and surgical wounds segment held the largest share of the market in 2019. The same segment is anticipated to register the highest CAGR in the market during the forecast period. The most common traumatic wounds are open fractures, avulsions, and penetrating wounds. According to data published by Centers of Disease Control and Prevention (CDC) in 2019, ~800,000 patients get hospitalized in the US for hip injuries each year. Furthermore, ~300,000 adult patients get hospitalized due to hip fractures. As per the HCUP Statistical Brief, ~22 million visits—of the total annual visits—were reported in the emergency department for the treatments of trauma and accident injury in the US. The growing number of road accidents and sports injuries favors the market growth for traumatic and surgical wounds segment.

End User-Based Insights

Based on end user, the biofilms treatment market is segmented into hospitals, home care settings, and other end users. The hospitals segment held the largest share of the market in 2019. Also, the same segment is estimated to register the highest CAGR in the market during the forecast period. The growth of the market for this segment is attributed to the increasing incidence of burn injuries across the world, especially in low-income countries. Hospitals are the primary healthcare centers approached by a patient seeking first aid and treatment for injuries. In general, patients prefer to visit clinics and hospitals than other healthcare centers. These centers offer various services and good quality treatment, with quick availability of the required equipment. Moreover, the fees for the treatments are reimbursed.

Strategic Insights

Various companies operating in the biofilms treatment market perform strategies such as product launches, mergers and acquisitions, collaborations, product innovations, and product portfolio expansions to expand their footprint worldwide, maintain the brand name, and meet the growing demand from end users.

Biofilms Treatment Market – by Product

• Gauzes and Dressings
• Debridement Equipment
• Grafts and Matrices
• Other Product

Biofilms Treatment Market – by Wound Type

• Traumatic and Surgical Wounds
• Diabetic Foot Ulcers
• Pressure Ulcers
• Venous Leg Ulcers
• Other Wounds

Biofilms Treatment Market – by End User

• Hospitals
• Home Care Settings
• Other End Users

Biofilms Treatment Market – by Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe

• Asia Pacific(APAC)

  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC

• Middle East and Africa (MEA)

  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

• South America (SAM)

  • Brazil
  • Argentina
  • Rest of SAM

Company Profiles

• Smith & Nephew plc
• MiMedx Group Inc.
• ConvaTec Group plc
• Coloplast A/S 
• Mölnlycke Healthcare AB
• Organogenesis Holdings Inc.
• Integra LifeSciences Holdings Corporation
• B. Braun Melsungen AG 
• PAUL HARTMANN AG
• Medline Industries Inc.